Mechanisms of gram‑positive vancomycin resistance (Review)
- Authors:
- Samy Selim
-
Affiliations: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72341, Kingdom of Saudi Arabia - Published online on: November 26, 2021 https://doi.org/10.3892/br.2021.1490
- Article Number: 7
This article is mentioned in:
Abstract
|
Stogios PJ and Savchenko A: Molecular mechanisms of vancomycin resistance. Protein Sci. 29:654–669. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Barna JC and Williams DH: The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 38:339–357. 1984.PubMed/NCBI View Article : Google Scholar | |
|
Griffith RS: Vancomycin use - an historical review. J Antimicrob Chemother. 14 (Suppl D):1–5. 1984.PubMed/NCBI View Article : Google Scholar | |
|
Mühlberg E, Umstätter F, Kleist C, Domhan C, Mier W and Uhl P: Renaissance of vancomycin: Approaches for breaking antibiotic resistance in multidrug-resistant bacteria. Can J Microbiol. 66:11–16. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds PE: Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 8:943–950. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Morrison D, Woodford N and Cookson B: Enterococci as emerging pathogens of humans. J Appl Microbiol. 83 (Suppl 1):89S–99S. 1997.PubMed/NCBI | |
|
Arthur M, Molinas C, Depardieu F and Courvalin P: Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol. 175:117–127. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Brisson-Noël A, Dutka-Malen S, Molinas C, Leclercq R and Courvalin P: Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147. Antimicrob Agents Chemother. 34:924–927. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Noble WC, Virani Z and Cree RGA: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 72:195–198. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Woodford N: Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist. 7:229–236. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P and Walsh CT: Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry. 30:10408–10415. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Pootoolal J, Neu J and Wright GD: Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol. 42:381–408. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Bugg TD, Dutka-Malen S, Arthur M, Courvalin P and Walsh CT: Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity. Biochemistry. 30:2017–2021. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Arthur M, Molinas C, Dutka-Malen S and Courvalin P: Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene. 103:133–134. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds PE, Depardieu F, Dutka-Malen S, Arthur M and Courvalin P: Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol Microbiol. 13:1065–1070. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Wu Z, Wright GD and Walsh CT: Overexpression, purification, and characterization of VanX, a D-, D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry. 34:2455–2463. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Arthur M and Quintiliani R Jr: Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 45:375–381. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Arthur M, Depardieu F, Gerbaud G, Galimand M, Leclercq R and Courvalin P: The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction. J Bacteriol. 179:97–106. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Arthur M, Depardieu F, Molinas C, Reynolds P and Courvalin P: The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene. 154:87–92. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Arthur M, Molinas C and Courvalin P: Sequence of the vanY gene required for production of a vancomycin-inducible D,D-carboxypeptidase in Enterococcus faecium BM4147. Gene. 120:111–114. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Evers S, Sahm DF and Courvalin P: The VanB gene of Enterococcus faecalis V583 is structurally related to genes encoding D-Ala-D-Ala ligases and glycopeptide resistance proteins VanA and VanC. Gene. 124:143–144. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Hayden MK, Picken RN and Sahm DF: Heterogeneous expression of glycopeptide resistance in enterococci associated with transfer of vanB. Antimicrob Agents Chemother. 41:872–874. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Poyart C, Pierre C, Quesne G, Pron B, Berche P and Trieu-Cuot P: Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother. 41:24–29. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Baptista M, Depardieu F, Courvalin P and Arthur M: Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother. 40:2291–2295. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Billot-Klein D, Gutmann L, Sablé S, Guittet E and van Heijenoort J: Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol. 176:2398–2405. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Boyle-Valva S, Berke SK, Lee JC and Daum RS: Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicob Agents Chemother. 44:272–277. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Cercenado E, García-Leoni ME, Díaz MD, Sánchez-Carrillo C, Catalán P, De Quirós JC and Bouza E: Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol. 34:1765–1768. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Clark NC, Teixeira LM, Facklam RR and Tenover FC: Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci. J Clin Microbiol. 36:2294–2297. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Solh N, et al: Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 41:5–14. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Dahl KH, Simonsen GS, Olsvik O and Sundsfjord A: Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 43:1105–1110. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Dever LL, Smith SM, Handwerger S and Eng RH: Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy. J Clin Microbiol. 33:2770–2773. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Dunne WM Jr, Qureshi H, Pervez H and Nafziger DA: Staphylococcus epidermidis with intermediate resistance to vancomycin: Elusive phenotype or laboratory artifact? Clin Infect Dis. 33:135–137. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Dutka-Malen S, Blaimont B, Wauters G and Courvalin P: Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 38:1675–1677. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Dutka-Malen S, Leclercq R, Coutant V, Duval J and Courvalin P: Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrob Agents Chemother. 34:1875–1879. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Eliopoulos GM: Vancomycin-resistant enterococci. Mechanism and clinical relevance. Infect Dis Clin North Am. 11:851–865. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Fahmy K and El-Hendi Y: Emergence of glycopeptide non-susceptible coagulase negative staphylococci among renal failure patients undergoing peritoneal dialysis. Egypt J Med Microbiol. 11:349–356. 2002. | |
|
Fines M, Perichon B, Reynolds P, Sahm DF and Courvalin P: VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother. 43:2161–2164. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Fridkin SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis. 32:108–115. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Geisel R, Schmitz FJ, Fluit AC and Labischinski H: Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 20:685–697. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis. 1:147–155. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Asadpour L and Ghazanfari N: Detection of vancomycin nonsusceptible strains in clinical isolates of Staphylococcus aureus in northern Iran. Int Microbiol. 22:411–417. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S and Kouhsari E: Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates. Antimicrob Resist Infect Control. 10(101)2021.PubMed/NCBI View Article : Google Scholar | |
|
Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med. 342:710–721. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Nicas TI, Cole CT, Preston DA, Schabel AA and Nagarajan R: Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 33:1477–1481. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C, Venkataraman L, Samore MH, Tenover FC, Eliopoulos GM, Moellering RC Jr and Gold HS: A cluster of VanD vancomycin-resistant Enterococcus faecium: Molecular characterization and clinical epidemiology. J Infect Dis. 180:1177–1185. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Perichon B, Reynolds P and Courvalin P: VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother. 41:2016–2018. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Rajashekaraiah KR, Rice T, Rao VS, Marsh D, Ramakrishna B and Kallick CA: Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis. Ann Intern Med. 93:796–801. 1980.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds PE, Snaith HA, Maguire AJ, Dutka-Malen S and Courvalin P: Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. Biochem J. 301:5–8. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Rodriguez-Cerrato V, McCoig CC, Saavedra J, Barton T, Michelow IC, Hardy RD, Bowlware K, Iglehart J, Katz K and McCracken GH Jr: Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother. 47:211–215. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Rybak MJ and Akins RL: Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: Clinical significance and treatment options. Drugs. 61:1–7. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S and Dar ban Sarokhalil DJ: Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta analysis. Sci Rep. 10:1–16. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sieradzki K, Villari P and Tomasz A: Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 42:100–107. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Cong Y, Yang S and Rao X: Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J Adv Res. 21:169–176. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Walsh TR and Howe RA: The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol. 56:657–675. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Wong SSY, Ho PL, Woo PCY and Yuen KY: Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis. 29:760–767. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Tacconelli E, Tumbarello M, Donati KG, Bettio M, Spanu T, Leone F, Sechi LA, Zanetti S, Fadda G and Cauda R: Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: Epidemiological and clinical findings from a case-control study. Clin Infect Dis. 33:1628–1635. 2001.PubMed/NCBI View Article : Google Scholar |
